Moodease

Hypericum perforatum dry extract, the active ingredient in Moodease, is a herbal extract presented as an oral preparation for oral use. It is traditionally used to support mood balance in adults.

GNH USA supplies Moodease as a licensed, GDP-compliant international pharmaceutical supplier serving pharmacies and clinics worldwide.

Moodease contains Hypericum perforatum dry extract, which is employed in the management of mood‑related conditions. - Mild to moderate depression: may help improve mood and emotional wellbeing. - Seasonal affective disorder: may alleviate low mood during winter months. - Mild anxiety: may support reduction of nervous tension.

Common Side Effects: - Gastrointestinal upset: nausea, stomach discomfort, or diarrhoea. - Dry mouth: reduced salivation causing a parched feeling. - Dizziness or light‑headedness, especially when standing quickly. - Fatigue or mild drowsiness. - Headache: occasional tension‑type pain. - Photosensitivity: increased skin sensitivity to sunlight.

Serious or Rare Side Effects: - Serotonin syndrome: risk when combined with other serotonergic agents. - Severe allergic reactions: rash, itching, swelling, or anaphylaxis. - Significant liver enzyme alterations: possible hepatic stress. - Manic or hypomanic episodes in predisposed individuals. - Severe photosensitivity leading to sunburn or skin damage.

When considering Moodease, several safety measures are recommended. - Pregnancy: avoid use unless specifically advised by a healthcare professional. - Breastfeeding: consult a physician before use. - Drug interactions: review all concurrent serotonergic medications. - Photosensitivity: limit sun exposure and use sunscreen. - Liver disease: use with caution and monitor hepatic function. - Store at ambient temperature: keep in the original pack, protect from moisture and light.

Moodease may interact with various medicines; awareness of the interaction level is important. Major Interactions (Avoid): - Selective serotonin reuptake inhibitors (SSRIs): risk of serotonin syndrome. - Monoamine oxidase inhibitors (MAOIs): potential for severe hypertensive reactions. - Tricyclic antidepressants: increased serotonergic activity. - Other serotonergic agents (e.g., tramadol, linezolid): heightened serotonin toxicity. - Anticoagulants (e.g., warfarin): possible enhanced anticoagulant effect. Moderate Interactions (Monitor Closely): - Oral contraceptives: may reduce efficacy. - Cyclosporine: possible altered blood levels. - Digoxin: potential increase in serum concentration. - Certain antiretrovirals: may affect drug metabolism. - Benzodiazepines: enhanced sedative effect.